Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology · Hereditary Transthyretin (ATTRv) Amyloidosis

How to Tell ATTRv V30M From CIDP & Diabetic Neuropathy?

At a Glance

ATTRv V30M amyloidosis is often misdiagnosed as CIDP or diabetic neuropathy because all cause similar nerve pain. However, ATTRv does not respond to CIDP treatments like IVIG. Red flags for ATTRv include severe digestive issues, bilateral carpal tunnel syndrome, and a family history.

In this answer

4 sections

01

Why ATTRv is Mistaken for CIDP

02

Why ATTRv is Mistaken for Diabetic Neuropathy

03

The “Red Flags” for ATTRv V30M Amyloidosis

04

Confirming the Diagnosis and Next Steps

It is completely understandable to be confused by a changed diagnosis. Unfortunately, diagnostic delays of three to five years are extremely common for patients with hereditary transthyretin (ATTRv) amyloidosis, specifically the V30M variant [1]. Because the initial symptoms of ATTRv V30M look remarkably similar to other types of nerve damage, patients are frequently misdiagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or diabetic neuropathy before the true cause is discovered [2][3].

While all three conditions cause peripheral polyneuropathy (numbness, tingling, pain, and weakness, typically starting in the feet), they originate from completely different causes. Diabetic neuropathy is caused by chronic high blood sugar damaging nerve endings [4]. CIDP is an autoimmune condition where the body mistakenly attacks the protective coating of the nerves, called the myelin sheath [5]. ATTRv V30M amyloidosis, on the other hand, is caused by a genetic mutation that makes the liver produce unstable transthyretin proteins. These proteins misfold into “amyloid fibrils” that deposit directly into the nerves and other organs, causing progressive damage [6][7].

Getting the correct diagnosis is critical because the treatments for these conditions are entirely different. While ATTRv V30M does not respond to diabetes or CIDP medications, there are now highly effective, disease-modifying therapies (such as gene silencers and stabilizers) specifically designed to target and halt ATTRv progression.

Here is how doctors can tell the difference between ATTRv V30M, CIDP, and diabetic neuropathy.

Why ATTRv is Mistaken for CIDP

When a doctor runs an EMG (electromyography) or nerve conduction study, they are measuring how fast electrical signals travel through your nerves. In CIDP, the loss of the myelin sheath slows these signals down—a pattern called “demyelination.”

Interestingly, as amyloid proteins damage the nerves in ATTRv amyloidosis, the resulting damage can mimic these exact same demyelinating patterns on an EMG, leading doctors to assume the patient has CIDP [5][8]. This is often referred to as “pseudo-demyelination” [5].

The IVIG Red Flag

The most significant clue that a patient has ATTRv amyloidosis rather than CIDP is their response to treatment. Because CIDP is driven by inflammation, patients typically see their symptoms stabilize or improve when given treatments like IVIG (intravenous immunoglobulin) or steroids [9][10].

ATTRv amyloidosis is not caused by inflammation. If you have been diagnosed with CIDP but your nerve damage has continued to aggressively progress despite IVIG or steroid therapy, this is a major “red flag” that should immediately prompt your medical team to investigate for ATTRv [9][11].

Why ATTRv is Mistaken for Diabetic Neuropathy

Both ATTRv V30M and diabetic neuropathy commonly present as a length-dependent small-fiber polyneuropathy [4][12]. This means the damage starts in the longest nerves of the body (the toes and feet) and slowly travels upward in a “stocking-glove” pattern.

However, diabetic neuropathy generally develops over many years of poorly controlled blood sugar. If a patient with well-managed diabetes, or only mild pre-diabetes, rapidly develops severe and painful nerve damage, doctors must look for a different underlying cause like ATTRv [4].

The “Red Flags” for ATTRv V30M Amyloidosis

To firmly differentiate ATTRv V30M from CIDP or diabetic neuropathy, doctors look for a specific cluster of clues outside of standard nerve pain. Because amyloid proteins build up throughout the entire body, ATTRv is a multisystem disease [13].

If you have neuropathy alongside any of these red flags, it points strongly toward ATTRv V30M:

  • Severe Autonomic Symptoms: The autonomic nervous system controls automatic body functions. While advanced diabetes can cause mild autonomic issues, ATTRv frequently causes severe, debilitating gastrointestinal problems (like alternating diarrhea and constipation), unexplainable weight loss, and severe dizziness or fainting when standing up (orthostatic hypotension) [14][15][16][17].
  • Bilateral Carpal Tunnel Syndrome: Numbness, tingling, and pain in the hands (carpal tunnel) in both wrists is a classic early sign of amyloid protein buildup in the ligaments of the wrists [18][19]. This often requires surgery and frequently appears years before the leg neuropathy begins [14].
  • Heart Issues: Unexplained thickening of the heart walls or early heart failure (cardiomyopathy) is common in ATTR amyloidosis as amyloid deposits in the heart muscle [20][21]. Symptoms might include shortness of breath with mild exertion or swelling in your ankles. While the V30M variant is most famous for its severe nerve damage, heart involvement is a critical difference between it and CIDP.
  • Family History: A family tree showing blood relatives who suffered from “mysterious” nerve problems, early need for a pacemaker, or undiagnosed heart failure is one of the most powerful diagnostic clues for hereditary ATTRv V30M [22].

Confirming the Diagnosis and Next Steps

If these red flags are present, your doctor can definitively distinguish ATTRv from CIDP and diabetic neuropathy through genetic testing for the TTR mutation, alongside specialized tests to detect the amyloid deposits [6][23].

These tests may include a tissue biopsy—often done with a minimally invasive sample from the abdominal fat pad or skin—and specialized heart imaging (like a PYP or DPD scan, which use safe tracers to highlight amyloid in the heart) [24]. However, because early-onset V30M primarily attacks the nerves, a patient might have a clear heart scan but still have the disease, making the genetic test and tissue biopsy the most reliable confirmations [6].

Because ATTRv is a hereditary condition, learning you have this gene mutation also means your siblings or children might be at risk. Working with a genetic counselor is a critical step to ensure your family gets the information and monitoring they need. Though this diagnosis is life-changing, getting the right answer finally opens the door to treatments that target the actual disease.

Common questions in this guide

Why is ATTRv V30M amyloidosis often misdiagnosed as CIDP?
ATTRv causes nerve damage that can mimic the 'demyelination' patterns seen on an EMG for CIDP. This pseudo-demyelination leads doctors to initially suspect CIDP, an autoimmune condition, before realizing the true cause is amyloid protein buildup.
What does it mean if my neuropathy is not responding to IVIG?
If your nerve damage continues to aggressively progress despite IVIG or steroid therapies, it is a major red flag that your condition is not caused by inflammation. This lack of response should prompt your doctor to investigate for non-inflammatory conditions like ATTRv amyloidosis.
How is ATTRv different from diabetic neuropathy?
While both conditions cause numbness and pain starting in the feet, diabetic neuropathy usually develops over many years of high blood sugar. If severe nerve pain develops rapidly in someone with well-managed diabetes, doctors should look for other causes like ATTRv.
What are the red flag symptoms of ATTRv amyloidosis?
Key warning signs outside of standard nerve pain include severe digestive issues, extreme dizziness when standing up, carpal tunnel syndrome in both wrists, unexplained heart problems, and a family history of mysterious nerve or heart conditions.
How do doctors confirm a diagnosis of ATTRv V30M?
Doctors definitively diagnose ATTRv using genetic testing to identify the TTR mutation. They may also use tissue biopsies from the abdominal fat pad or skin, as well as specialized heart scans, to detect where amyloid protein deposits have formed in the body.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my lack of response to IVIG and steroid therapies, could my nerve conduction tests be showing secondary nerve damage from amyloidosis rather than primary demyelination?
  2. 2.Now that we know I have ATTRv V30M, should I be evaluated by a cardiologist for a PYP scan or an echocardiogram to check for heart involvement?
  3. 3.Are my gastrointestinal symptoms and dizzy spells caused by autonomic neuropathy from amyloidosis, and how can we manage those?
  4. 4.What disease-modifying therapies, like TTR silencers or stabilizers, am I a candidate for to help stop the progression of my neuropathy?
  5. 5.Can you refer me to a genetic counselor so we can discuss the best way to test and monitor my children and siblings?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

ATTRv V30M Medications: Pills, Shots, or IV Infusions?How Does ATTRv V30M Amyloidosis Affect Eye Health?Talk to Family About ATTRv V30M Genetic TestingHow to Manage Dizziness & GI Issues in ATTRv AmyloidosisAre V30M and p.Val50Met the Same Genetic Mutation?What Is the ATTRv V30M Carrier Monitoring Protocol?Is Liver Transplant Still Used for V30M Amyloidosis?What Is the sNfL Test for ATTRv V30M Amyloidosis?Questions to Ask an ATTRv V30M Amyloidosis SpecialistWho is at Risk for ATTRv V30M Amyloidosis?Why Do PYP Scans Miss Heart Amyloidosis in V30M?Why Do TTR Silencers Require Vitamin A Supplements?

References

References (24)
  1. 1

    Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.

    Carroll A, Dyck PJ, de Carvalho M, et al.

    Journal of neurology, neurosurgery, and psychiatry 2022; (93(6)):668-678 doi:10.1136/jnnp-2021-327909.

    PMID: 35256455
  2. 2

    Phenotypes of Late-Onset Transthyretin Amyloid Neuropathy: A Diagnostic Challenge.

    Živković SA, Mnatsakanova D, Lacomis D

    Journal of clinical neuromuscular disease 2019; (21(1)):1-6 doi:10.1097/CND.0000000000000252.

    PMID: 31453848
  3. 3

    Electrophysiological demyelinating features in hereditary ATTR amyloidosis.

    Ohashi N, Kodaira M, Morita H, Sekijima Y

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(1)):15-23 doi:10.1080/13506129.2018.1564903.

    PMID: 30688105
  4. 4

    Hereditary transthyretin-related amyloidosis.

    Finsterer J, Iglseder S, Wanschitz J, et al.

    Acta neurologica Scandinavica 2019; (139(2)):92-105 doi:10.1111/ane.13035.

    PMID: 30295933
  5. 5

    Significance of aberrant nerve conduction in hereditary transthyretin amyloidosis.

    Ide T, Yoshikawa M, Suzuyama K, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2026; 1-9 doi:10.1080/13506129.2026.2613126.

    PMID: 41524533
  6. 6

    "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.

    Conceição I, González-Duarte A, Obici L, et al.

    Journal of the peripheral nervous system : JPNS 2016; (21(1)):5-9 doi:10.1111/jns.12153.

    PMID: 26663427
  7. 7

    Pearls & Oy-sters: Number, Weaker, and Dizzier Due to Transthyretin Amyloidosis After 2 Liver Transplants.

    Yerevanian AI, Shu F

    Neurology 2021; (96(7)):e1088-e1091 doi:10.1212/WNL.0000000000011289.

    PMID: 33277417
  8. 8

    The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: An ultrastructural study.

    Koike H, Nishi R, Ikeda S, et al.

    Journal of the neurological sciences 2018; (394()):99-106 doi:10.1016/j.jns.2018.09.011.

    PMID: 30243104
  9. 9

    Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study.

    Péréon Y, Adams D, Camdessanché JP, et al.

    Orphanet journal of rare diseases 2025; (20(1)):95 doi:10.1186/s13023-025-03589-4.

    PMID: 40025610
  10. 10

    Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes.

    Breiner A, Barnett Tapia C, Lovblom LE, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2019; (6(5)) doi:10.1212/NXI.0000000000000586.

    PMID: 31454771
  11. 11

    Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis.

    Doneddu PE, Moretti G, Di Stefano V, et al.

    Journal of neurology 2025; (272(8)):515 doi:10.1007/s00415-025-13218-6.

    PMID: 40670759
  12. 12

    Familial Amyloid Polyneuropathy.

    Çakar A, Durmuş-Tekçe H, Parman Y

    Noro psikiyatri arsivi 2019; (56(2)):150-156 doi:10.29399/npa.23502.

    PMID: 31223250
  13. 13

    Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.

    Adams D, Algalarrondo V, Polydefkis M, et al.

    Orphanet journal of rare diseases 2021; (16(1)):411 doi:10.1186/s13023-021-01960-9.

    PMID: 34602081
  14. 14

    [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].

    Niemietz C, Röcken C, Schilling M, et al.

    Deutsche medizinische Wochenschrift (1946) 2018; (143(6)):427-430 doi:10.1055/s-0043-123681.

    PMID: 29544239
  15. 15

    Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.

    Chiaro G, Stancanelli C, Koay S, et al.

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2024; (34(3)):341-352 doi:10.1007/s10286-024-01038-z.

    PMID: 38769233
  16. 16

    Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis.

    Obici L, Suhr OB

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2019; (29(Suppl 1)):55-63 doi:10.1007/s10286-019-00628-6.

    PMID: 31452022
  17. 17

    Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis.

    Martínez-Valle F, Casasnovas-Pons C, Romero-Acebal M, Galán-Dávila L

    Neurologia 2025; (40(9)):915-923 doi:10.1016/j.nrleng.2025.08.002.

    PMID: 41198384
  18. 18

    Hereditary ATTR Amyloidosis with Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S).

    Nakase T, Yamashita T, Matsuo Y, et al.

    Internal medicine (Tokyo, Japan) 2019; (58(18)):2695-2698 doi:10.2169/internalmedicine.2456-18.

    PMID: 31178489
  19. 19

    Association between spinal stenosis and wild-type ATTR amyloidosis.

    Godara A, Riesenburger RI, Zhang DX, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(4)):226-233 doi:10.1080/13506129.2021.1950681.

    PMID: 34263670
  20. 20

    Late-Onset Hereditary Transthyretin Amyloidosis Val30Met in an Elderly Person in a Non-Endemic Area.

    Wang S, Sun J, Lu Q, et al.

    International medical case reports journal 2022; (15()):299-306 doi:10.2147/IMCRJ.S357236.

    PMID: 35734096
  21. 21

    Progression of myocardial sympathetic denervation assessed by 123I-MIBG imaging in familial amyloid polyneuropathy and the effect of liver transplantation.

    Azevedo Coutinho MDC, Cortez-Dias N, Cantinho G, et al.

    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 2017; (36(5)):333-340 doi:10.1016/j.repc.2016.08.010.

    PMID: 28479268
  22. 22

    A rare pathogenic variant identified in a heart transplant recipient with hereditary transthyretin amyloidosis: a case report.

    Kim MS, Lee SY, Kim KH

    Journal of Yeungnam medical science 2023; (40(Suppl)):S98-S104 doi:10.12701/jyms.2023.00241.

    PMID: 37248693
  23. 23

    Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.

    Skrahina V, Grittner U, Beetz C, et al.

    Annals of medicine 2021; (53(1)):1787-1796 doi:10.1080/07853890.2021.1988696.

    PMID: 34658264
  24. 24

    Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.

    Leonardi L, Adam C, Beaudonnet G, et al.

    European journal of neurology 2022; (29(5)):1477-1487 doi:10.1111/ene.15268.

    PMID: 35100482

This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist or primary care provider about your specific diagnostic test results and treatment plan.

Get notified when new evidence is published on ATTRV30M amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.